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shown to be signiﬁcantly lower in ED patients than in
non-ED subjects (84.4 vs. 89.4, respectively; p = 0.0109),
suggesting an association between self-conﬁdence and
erectile dysfunction. CONCLUSION: Assessment of self-
conﬁdence through this Spanish version of the Johnson
and McCoy’s questionnaire is reliable and valid and pro-
vides a new instrument to measure the psychological
impact of erectile dysfunction.
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OBJECTIVE: There are currently no available psycho-
metric instruments that measure erection quality. A quan-
titative measure of erectile quality has potential value as
a measure in both clinical research and in the clinical
treatment of erectile dysfunction. The objective of this
study is to describe the development and evaluation of a
new patient-reported questionnaire, designed to measure
changes in erection quality. METHODS: Based on input
from interviews with men across the United States and
recommendations from an expert panel, seven constructs
were selected for inclusion in the questionnaire. Multiple
items were drafted to measure each of the key constructs,
which included various question wordings, formats, and
response category options. An iterative process of cogni-
tive testing, item revision, and item reduction led to the
identiﬁcation of ﬁfteen items and their optimal response
scales. At the completion of the cognitive testing, the psy-
chometric properties of the questionnaire were evaluated
as a part of a 200-subject test-retest study. Participants
were classiﬁed into ED-Untreated, ED-Treated, and
Normal Sexual Functioning groups in order to gather
information about how well the items differentiated
among men with different levels of erectile functioning.
RESULTS: The psychometric evaluation demonstrated no
ﬂoor or ceiling effects. The study results supported a
strong one-factor structure, indicating that the EQS
should be reported using one overall score. Internal con-
sistency is supported with Cronbach alpha values of 0.94
and 0.95 (for visit 1 and 2, respectively). An intraclass
correlation coefﬁcient of 0.79 denotes adequate test-retest
reliability. Furthermore, the EQS showed promise for dif-
ferentiating patients from the three classiﬁcations, ED-
Untreated, ED-Treated, and Normal Sexual Functioning,
a preliminary indication of discriminate validity. CON-
CLUSIONS: The results of the development and initial
evaluation of the EQS are favorable and provide evidence
of the questionnaire’s utility for measuring erection
quality. A future study is planned to demonstrate the
instrument’s responsiveness.
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OBJECTIVES: The assessment of a patient’s ability to
perform activities of daily life often directs the indication
for: 1) nursing home; 2) residential care; 3) sheltered
housing; or 4) homecare assistance. Currently, indications
in the Netherlands are based on Likert-scaled, thus
ordinal and difﬁcult to interpret, measurement of func-
tional performance. On the contrary, hierarchical scaling
of functional disability, based on item response theory
(IRT), may lead to quantitative, “tailor-made” indica-
tions and fewer misjudgements of the need for care. The
current study demonstrates the potential ﬁnancial impact
of IRT-based indications for two re-indication scenarios.
METHODS: Patients at the outpatient hospital clinic and
patients in long-term care facilities were scored with items
from a calibrated, IRT-based item bank. Distributions of
functional disability levels were compared for patients in
the four care settings respectively (N = 2524). Re-
indication to the “adjacent” care setting was assumed
preferable for the 10% or 25% best performing patients
in nursing homes, residential care and sheltered housing
settings. Unit costs of care per day were derived from a
national guideline. Home care assistance was assumed to
take two hours a day on average. Costs were expressed
in €2002. In the baseline scenario each care setting con-
tained 1000 patients. RESULTS: The costs per day in 
the baseline scenario were €318K per 4000 patients. In
the 10% and 25% re-indication scenarios, these costs
dropped to €308K and €295K respectively, correspond-
ing to 3% or 7.1% reductions of initial costs. CON-
CLUSIONS: Although psychosocial and environmental
aspects play a role during the indication process, a
patient’s functional performance remains the major direc-
tive for health care organisations to guide the distribution
of scarce resources among the elder community members.
IRT-based assessments may help to quantify the need for
care adequately and even lead to cost reductions in health
care.
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OBJECTIVES: Modelling and forecasting the con-
sequences of AIDS on economic growth in Africa.
METHODS: Our model is based on two crucial hypoth-
esis: AIDS has a short-term impact on a ﬂow variable (the
ﬂow of labour available and capable of working at a
moment t in the economy); AIDS has a long-term impact
on stock variables (human capital, i.e. the stock of health
or the stock of education and competence incorporated
in the workers; and physical capital). The ﬁrst effect is
generally taken into account in the existing literature but
the second is missing. Data from Ivory Coast (data given
by UNAIDS and WHO) about macroeconomic variables
and epidemiologic situations are used to calibrate our
model. RESULTS: Integrating these two impacts in a
model of growth with multiple factors of accumulation is
sufﬁcient to reverse the standard impact-evaluations
based on classical tools. We show that, under a realistic
range of epidemiological shocks, an involution trap can
appear, corresponding to a modiﬁcation of the long-term
growth regime of the economy. CONCLUSIONS: When
the long term impact of AIDS is taken into account, the
impact of AIDS on economic growth in Africa is far worse
than predicted by UNAIDS for instance. In Ivory Coast,
the GDP loss is about 15% of the no-AIDS scenario in
2010 (against -8% for the UNAIDS forecast).
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OBJECTIVES: To investigate the potential role of phar-
macoeconomics in decision making and education.
METHODS: A group of 102 people with backgrounds in
health economics/pharmacoeconomics was interviewed.
Interviewees were students (23), medical doctors (28),
pharmacists (36), managers/economists (22) by educa-
tion, working in hospitals, outpatient clinics, pharmacies,
and the pharmaceutical industry. They were asked about:
sources of information that should be used by decision
makers at different levels of a Health care sector, barriers
to practical application of pharmacoeconomic evaluation
results, criteria for inclusion/exclusion of drugs in a hos-
pital formulary, means by which economic evaluation uti-
lization could become more common, needs for education
initiatives. RESULTS: A total of 86% of responders indi-
cated that expert opinion and 66% that articles in
reviewed scientiﬁc journals are the most important source
of information for reimbursement decisions. At manage-
ment level, also expert opinion (77%) and scientiﬁc jour-
nals (65%) played a key role. In relations between
pharmacist / physician and patient, personal opinion is
vital (58%), followed by experts’ opinion (55%) and
information from scientiﬁc press (50%). Limited interest
in pharmacoeconomic analyses focusing only on cost-
containment (77%) followed by lack of Governmental
Agencies’ involvement in introduction of regulations
(61%), difﬁculties in applying long-term view (57%) and
limited access to cost data (lack of national cost database)
(57%) were recognized as main barriers. On inclusion to
hospital formulary, acquisition cost (70%) and efﬁcacy
(96%) were crucial, hospital savings were less important
(50%). Wider use of pharmacoeconomic studies may be
due to more educational initiatives (74%), creation of
professional cost databases (72%) and transparent crite-
ria of evaluation (69%). A total of 86% of responders
declared the need to expand their knowledge. CON-
CLUSIONS: Education, cost databases and regulations
seem to be the most important in the future development
of pharmacoeconomics and health economics in Poland.
Conﬁrmation of these preliminary results requires
broader investigation.
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OBJECTIVES: To identify the main causes of variation in
study results from place to place, to assess whether the
variation differs by type of health economic study, to
assess whether differences among countries are systematic
and whether the differences are important for decision-
making. METHODS: A literature search was conducted
to identify economic evaluations of pharmaceuticals 
conducted in two or more European countries. These
included reports of multicountry studies and separate
reports of single country studies that were sufﬁciently
methodologically comparable. The studies identiﬁed were
then classiﬁed by methodological type and analysed to
assess their level of generalizability and to identify the
main causes of variation. Assessments were also made of
the extent to which differences in study results among
countries were systematic and whether they would lead
to a different decision, assuming a range of values of the
threshold willingness-to-pay for a life-year or quality-
adjusted life-year (QALY). RESULTS: In total 46 
intercountry drug comparisons were identiﬁed, 29 in mul-
ticountry studies and 17 in single country studies that
were considered to be sufﬁciently comparable in terms of
methodology. The type of study (i.e. trial-based or mod-
elling study) had some impact on generalizability, but a
more important factor was the extent of variation across
countries, in effectiveness, resource use or unit costs,
allowed by the researcher’s chosen methodology. Cost-
effectiveness results did differ widely between countries
